EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

NEK2 inhibition alleviates lipopolysaccharide-induced endothelial injury

Saikat Fakir iD, Md Matiur Rahman Sarker, Madan Sigdel, Nektarios Barabutis iD

ASPET Discovery · 2025

DOI: 10.1016/j.aspetd.2025.100002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ASPET Discovery, 2025. Verfasst von Saikat Fakir und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, Louisiana. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, National Institutes of Health, NIH National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The endothelial barrier regulates substance transfer across an extensive surface area, and vascular leakage may contribute to various inflammatory conditions, including acute respiratory distress syndrome and sepsis. NEK2 possesses a significant role in regulating cellular processes, and its overexpression has been linked to human disease. The present study investigates the effects of NEK2 inhibitor NCL 00017509 in endothelial barrier dysfunction and inflammation. Our results indicate that the aforementioned compound effectively suppresses lipopolysaccharide-induced activation of Cofilin and MLC2, which are crucial cytoskeletal components. NEK2 inhibition reduced endothelial paracellular permeability, reactive oxygen species generation, and phosphorylation of key inflammatory proteins (eg, ERK1/2, P38, STAT1, and STAT3) in cells exposed to lipopolysaccharide. Further investigation into the application of NEK2 inhibitors in preclinical models of direct and indirect lung injury will substantiate our findings.

Schlagwörter

Stichwörter der Autor:innen

Endothelial permeabilityLungSepsis

Autor:innen und Institutionen

  • School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, Louisiana.

ORCID-Profile: Saikat Fakir, Nektarios Barabutis

Förderung

  • NIGMS NIH HHS
  • National Institutes of Health
  • NIH National Institute of General Medical Sciences

Zitieren

APA

Fakir, S., Sarker, M. M. R., Sigdel, M., & Barabutis, N. (2025). NEK2 inhibition alleviates lipopolysaccharide-induced endothelial injury. ASPET Discovery. https://doi.org/10.1016/j.aspetd.2025.100002

Vancouver

Fakir S, Sarker MMR, Sigdel M, Barabutis N. NEK2 inhibition alleviates lipopolysaccharide-induced endothelial injury. ASPET Discovery. 2025. doi:10.1016/j.aspetd.2025.100002

BibTeX
@article{Fakir2025,
  author = {Fakir, Saikat and Sarker, Md Matiur Rahman and Sigdel, Madan and Barabutis, Nektarios},
  title = {NEK2 inhibition alleviates lipopolysaccharide-induced endothelial injury},
  journal = {ASPET Discovery},
  year = {2025},
  doi = {10.1016/j.aspetd.2025.100002}
}
Kostenlos starten →